News
GLUE
11.71
-0.51%
-0.06
Weekly Report: what happened at GLUE last week (0921-0925)?
Weekly Report · 19h ago
What Monte Rosa Therapeutics (GLUE)'s Phase 2 Trial Start Means For Shareholders
Simply Wall St · 6d ago
Weekly Report: what happened at GLUE last week (0914-0918)?
Weekly Report · 09/21 10:24
Weekly Report: what happened at GLUE last week (0907-0911)?
Weekly Report · 09/14 10:30
Phase 2 Start Might Change The Case For Investing In Monte Rosa Therapeutics Stock (GLUE)
Simply Wall St · 09/09 13:20
Wedbush Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)
TipRanks · 09/09 12:55
Monte Rosa Therapeutics Price Target Maintained With a $27.00/Share by Wedbush
Dow Jones · 09/09 12:22
Wedbush Reiterates Outperform on Monte Rosa Therapeutics, Maintains $27 Price Target
Benzinga · 09/09 12:12
Analysts’ Top Healthcare Picks: IDEAYA Biosciences (IDYA), Monte Rosa Therapeutics (GLUE)
TipRanks · 09/09 11:30
Novartis-Backed MRT-6160 Expansion and Strong Partnership Economics Underpin Oliver McCammon’s Buy Rating on Monte Rosa’s GLUE
TipRanks · 09/08 19:35
Monte Rosa earns milestone as MRT-6160 enters Phase 2
TipRanks · 09/08 11:32
Monte Rosa Therapeutics to receive $50M milestone payment from Novartis
TipRanks · 09/08 11:10
Weekly Report: what happened at GLUE last week (0831-0904)?
Weekly Report · 09/07 10:23
How Investors Are Reacting To Monte Rosa Therapeutics (GLUE) Advancing MRT-2359 Into Phase 2 Prostate Cancer Trial
Simply Wall St · 09/06 10:24
Monte Rosa Therapeutics (GLUE), What Is Behind The Fresh Attention?
Simply Wall St · 09/04 14:32
Monte Rosa Therapeutics: High-Stakes Drug Pipeline Balanced By A Fortress Balance Sheet
Seeking Alpha · 09/03 13:06
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Barchart · 09/01 06:00
Weekly Report: what happened at GLUE last week (0824-0828)?
Weekly Report · 08/31 10:30
Is Monte Rosa Therapeutics (GLUE) Redefining Its Prostate Cancer Strategy With MRT-2359’s Phase 2 Combo Bet?
Simply Wall St · 08/27 12:28
Monte Rosa Therapeutics (GLUE) Looks Pricey As Phase 2 Progress Keeps The Story Alive
Simply Wall St · 08/25 23:24
More
Webull provides a variety of real-time GLUE stock news. You can receive the latest news about Monte Rosa Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About GLUE
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.